Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

EPS and iPS Cells in Disease Research01:21

EPS and iPS Cells in Disease Research

2.8K
Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...
2.8K
iPS Cell Differentiation01:22

iPS Cell Differentiation

2.6K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
2.6K
Clinical Applications of Epidermal Stem Cells01:19

Clinical Applications of Epidermal Stem Cells

2.7K
Epidermal stem cells (EpiSCs) are mainly located at the basal layer of the epidermis. These cells repair minor injuries of the skin and replace dead skin cells. However, EpiSCs’ cannot heal severe wounds such as major burns or those from diabetes or hereditary disorders. In such cases, culturing the epidermal stem cells from the patient is possible and has yielded successful treatment options, such as laboratory-grown skin grafts. These grafts are synthesized using a patient’s own...
2.7K
T Cell Types and Functions01:24

T Cell Types and Functions

954
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
954
Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

3.9K
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
3.9K
Skin Cancer01:30

Skin Cancer

3.8K
Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
3.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comment on 'Incidence and Mortality of Mucous Membrane Pemphigoid in France'.

The British journal of dermatology·2026
Same author

Hidradenitis suppurativa is associated with increased risk of lymphoma: An international analysis using TriNetX.

Journal of the American Academy of Dermatology·2026
Same author

A Cross-Sectional Study of YouTube Videos as a Source of Information Regarding Biologics for Hidradenitis Suppurativa.

Dermatology practical & conceptual·2026
Same author

Quality and Accuracy of Atopic Dermatitis Treatment Content on TikTok: A Cross-Sectional Analysis.

Dermatology practical & conceptual·2026
Same author

Racial Disparities and Climate Change in Dermatology.

Dermatology practical & conceptual·2026
Same author

Psoriasis and Obesity: A Clinical Review of the Bidirectional Link and Management Implications.

Cutis·2026
Same journal

The Evidence Is In: Devices and Biologics Reshaping Modern Dermatology.

Dermatologic clinics·2026
Same journal

Energy-Based Devices for Body Contouring.

Dermatologic clinics·2026
Same journal

Microfocused Ultrasound with Visualization for Skin Tightening: Clinical Applications, Safety, and Technical Considerations.

Dermatologic clinics·2026
Same journal

Devices in Onychomycosis: A Status Update.

Dermatologic clinics·2026
Same journal

Acne Laser Devices in Dermatology.

Dermatologic clinics·2026
Same journal

Fractional Laser Therapy for Androgenetic Alopecia: Mechanisms, Clinical Evidence, and Practical Implementation.

Dermatologic clinics·2026
See all related articles

Related Experiment Video

Updated: Jun 7, 2025

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

38.9K

Innovations in Psoriasis.

Amylee Martin1, Marina Kristy Ibraheim1, Rohit Gupta2

  • 1Department of Dermatology, Loma Linda University, 25865 Barton Road #101, Loma Linda, CA 92354, USA.

Dermatologic Clinics
|November 14, 2024
PubMed
Summary
This summary is machine-generated.

New psoriasis treatments, including topical agents, an oral small molecule, and a monoclonal antibody, offer hope for patients with unmet needs. These FDA-approved therapies and emerging options, like orismilast, advance psoriasis care.

Keywords:
BiologicsInnovationsPsoriasisTreatments

More Related Videos

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients
02:28

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients

Published on: March 1, 2024

338
Stimulation of Stem Cell Niches and Tissue Regeneration in Mouse Skin by Switchable Protoporphyrin IX-Dependent Photogeneration of Reactive Oxygen Species In Situ
10:05

Stimulation of Stem Cell Niches and Tissue Regeneration in Mouse Skin by Switchable Protoporphyrin IX-Dependent Photogeneration of Reactive Oxygen Species In Situ

Published on: May 8, 2020

1.9K

Related Experiment Videos

Last Updated: Jun 7, 2025

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

38.9K
Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients
02:28

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients

Published on: March 1, 2024

338
Stimulation of Stem Cell Niches and Tissue Regeneration in Mouse Skin by Switchable Protoporphyrin IX-Dependent Photogeneration of Reactive Oxygen Species In Situ
10:05

Stimulation of Stem Cell Niches and Tissue Regeneration in Mouse Skin by Switchable Protoporphyrin IX-Dependent Photogeneration of Reactive Oxygen Species In Situ

Published on: May 8, 2020

1.9K

Area of Science:

  • Dermatology and Immunology
  • Pharmacology

Background:

  • Psoriasis treatment has effective biologics, but unmet needs persist for specific patient groups.
  • Ongoing research aims to develop novel therapies for diverse psoriasis patient populations.

Purpose of the Study:

  • To review recently Food and Drug Administration (FDA)-approved therapies for psoriasis.
  • To highlight emerging treatments and predictive tools in the psoriasis pipeline.

Main Methods:

  • Review of recent FDA-approved psoriasis treatments.
  • Discussion of novel therapeutic agents and predictive response tools.

Main Results:

  • Recent FDA approvals include topical tapinarof and roflumilast, oral deucravacitinib (tyrosine kinase 2 inhibitor), and spesolimab (IL-36 inhibitor) for generalized pustular psoriasis.
  • Emerging therapies like orismilast and predictive tools such as Mind.Px are under investigation.

Conclusions:

  • Recent advancements provide new therapeutic options for psoriasis patients, addressing unmet needs.
  • The pipeline includes promising oral, topical, and biologic agents, alongside tools to personalize treatment.